慢性肾脏病走到十字路口:从失败中走向未来治疗
本综述讨论慢性肾脏病(CKD)已有肾脏和心脏获益的药物治疗,重点分析实施障碍与正在进行的临床试验,并介绍晚期临床试验中的新疗法及个性化管理需求,同时提及虽有生理学依据但未显示临床获益的治疗策略。
要点
- CKD是公共卫生紧急事件,疾病负担与死亡率持续增加。
- 已获批的护肾护心疗法在临床实践中使用率低于预期。
- 早期识别CKD是治疗前提,但筛查与成本效益仍存全球争议。
核心结论
- CKD治疗选择已从有限扩展为多种获批疗法及有前景的在研药物。
- 已证实肾脏和心脏获益的疗法在临床中应用不足,存在知-行差距。
- 未来需个性化管理以确定哪些疗法最适合哪些患者。
研究设计与样本
- 综述类文章,检索范围未在摘要中具体报告。
主要发现
- 已获批疗法有强证据和指南推荐支持广泛使用,但实际 uptake 低于预期。
- 多项晚期临床试验可能在未来几年扩大CKD治疗选择。
- 部分治疗策略虽有合理生理学支持,但未显示临床获益。
临床怎么用
- 临床医生应关注已证实肾脏和心脏获益的获批疗法并提高使用率。
- 需早期识别CKD以启动治疗,同时考虑筛查的成本效益争议。
- 关注晚期临床试验结果以更新常规临床实践。
局限性
- 全球可及性和可负担性面临挑战。
- 筛查与成本效益在全球范围内仍存争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is a public health emergency because it is common and carries an increasing burden of morbidity and mortality. Until recently, treatment options for CKD and its adverse systemic effects were limited; however, we now have multiple approved therapies and a growing pipeline of promising treatments under evaluation. Despite the strong evidence and guideline recommendations supporting the broad use of approved therapies, uptake in practice remains lower than expected, potentially limiting the benefits of these advances. Early identification of CKD remains a prerequisite for therapy, yet screening and cost-effectiveness continue to be debated globally. In this review, we discuss the currently available pharmacologic treatments for CKD that have proven kidney and cardiac benefits with a specific focus on addressing barriers to implementation and ongoing trials that will inform their routine clinical use. We then discuss treatments that are in late-phase clinical trials that may expand the therapeutic options for CKD in the next few years. This will necessitate a personalized approach to management to determine which therapies will work best for which patients. Finally, we touch on therapeutic strategies that did not demonstrate clinical benefits despite rational physiologic support. This review addresses the know-do gap that exists in applying proven therapies for people with CKD and provides clinicians with practical tools and knowledge to improve clinical uptake, while acknowledging global challenges of access and affordability.
引用
- Wehbe F, Elliott M, Levin A, et al. CKDs at the Crossroads: From Failures to Future Therapies. Kidney Int Rep. 2025. PMID: 41426032. doi:10.1016/j.ekir.2025.09.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。